Intech Biopharm Ltd (6461.TWO) stock: key figures, P/E, revenue and dividend
Health Care · Biotechnology · Taiwan · ISIN TW0006461007
Intech Biopharm Ltd financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 39.78 m TWD | 107.53 m TWD |
| Gross profit | -157.63 m TWD | -110.94 m TWD |
| Operating income | -356.13 m TWD | -364.50 m TWD |
| EBIT | -334.05 m TWD | -348.71 m TWD |
| Net income | -368.21 m TWD | -389.03 m TWD |
| Diluted EPS – continuing operations | -2.63 TWD | -2.18 TWD |
Full history since 2017, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Intech Biopharm Ltd
Intech Biopharm Corporation engages in developing and manufacturing generic drugs to treat respiratory diseases in Taiwan and internationally. The company offers combinations, formulations, and generic drugs for the treatment of respiratory diseases using technology platforms, such as inhaled low ethanol formulation, a metered dose inhaler platform for treating asthma and COPD, as well as dry powder inhaler that comprises blisters and capsules. Its products include SYN006, SYN010, SYN007, Synflutide, Duasma,Synvent, and SYN011. The company was founded in 2010 and is headquartered in Taipei, Taiwan.
More stocks
- Media Nusantara Citra Tbk PT (MNCN.JK)
- Wavice Inc. (289930.KQ)
- SurplusGLOBAL, Inc. (140070.KQ)
- Mercuries F&B Co., Ltd. (7705.TW)
- Mgame Corp (058630.KQ)
- iNtRON Biotechnology Inc (048530.KQ)
- H.H.Galaxy Co., Ltd. (2949.TWO)
- Cs Holdings (000590.KS)
- Taiwan Ostor (8080.TWO)
- TJ media Co. Ltd (032540.KQ)
- Everspring Industry Co Ltd (2390.TW)
- Forcera Materials Co., Ltd. (3467.TWO)
Not investment advice. All data without warranty, price as of 16.11.2026. Details in the risk notice.